LDLR and atherosclerosis: Moreover, in mice deficient in hepatic LDLR and LRP1, APOC3 inhibition had little effect on plasma lipids and had no beneficial effects on advanced atherosclerosis, as opposed to mouse models in which APOC3 silencing lowers lipids (11), suggesting that enhanced inflammatory processes might not contribute in major ways to the pro-atherogenic effects of APOC3.